膀胱癌组织学变异对肌层浸润性和转移性膀胱癌预后及治疗的重要性:欧洲泌尿外科学会指南小组系统综述
该系统性综述探讨了肌层浸润性(MIBC)和转移性(mBC)膀胱癌中组织学变异对肿瘤学结局的预后影响及治疗意义。共纳入41项研究、27 672例组织学变异患者,多数研究为中等偏倚风险;印戒细胞、梭形细胞和神经内分泌肿瘤生存劣于纯尿路上皮癌,所有MIBC患者应行根治性膀胱切除术,新辅助化疗可能对微乳头状、浆细胞样、肉瘤样及混合变异(尤其神经内分泌肿瘤)有益。
要点
- 印戒细胞、梭形细胞和神经内分泌变异预后差于纯尿路上皮癌。
- 所有MIBC患者均应接受根治性膀胱切除术。
- 微乳头状、浆细胞样、肉瘤样及混合变异可能从新辅助化疗获益。
核心结论
- 组织学变异预后数据尚不成熟且多基于膀胱切除患者,但不同变异结局存在差异,治疗应基于组织学发现。
研究设计与样本
- 偏倚风险采用Quality in Prognosis Studies工具评估,多数研究为中等风险。
主要发现
- 大多数组织学变异在根治性膀胱切除术后肿瘤学结局相似。
- 印戒细胞、梭形细胞和神经内分泌肿瘤与纯尿路上皮癌相比生存更差。
- 研究间存在较大异质性,故采用叙述性综合而非亚组分析。
临床怎么用
- 所有MIBC患者应接受根治性膀胱切除术。
- 微乳头状、浆细胞样、肉瘤样和混合变异可能从新辅助化疗获益,神经内分泌肿瘤尤其可能获益。
- 转移性膀胱癌应按纯尿路上皮癌治疗。
局限性
- 组织学变异的预后和治疗数据尚不成熟。
- 证据主要来自膀胱切除患者。
- 研究间存在较大异质性,部分研究缺乏集中病理复审。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Variant histology of muscle-invasive (MIBC) and metastatic (mBC) bladder cancer may define the cancer treatment modality and oncological outcomes. OBJECTIVE: To determine the prognostic effect and impact of therapy of urothelial and nonurothelial histological variants on the oncological outcomes of MIBC and mBC. EVIDENCE ACQUISITION: Medline, Embase, Cochrane controlled trial databases, and ClinicalTrials.gov were systematically searched. Patients with histological variants of MIBC or/and mBC from prospective and retrospective comparative studies and single-arm case series published after the year of 2000 were included. Treatment outcomes (overall, recurrence-free, and disease-specific survival) were extracted and reported. Risk of bias (RoB) assessment was performed using Quality in Prognosis Studies tool. EVIDENCE SYNTHESIS: The search yielded 2450 unique articles, of which 41 articles involving a total of 27 672 patients with histological variants were included. Twenty-eight studies had a comparative study design. Two different study settings were seen: large database studies without centralised pathological review and small series with re-review by uropathologists. Although most of the histological variants show similar oncological outcomes after radical cystectomy (RC), signet ring cell, spindle cell, and neuroendocrine tumours showed inferior survival compared with pure urothelial bladder cancer (PUC). Owing to potential misleading interpretations and reporting as well as large heterogeneity between studies, a narrative synthesis approach instead of subgroup analyses was used. Most studies had a moderate RoB. CONCLUSIONS: The data about prognosis and treatment of the variant histology are still immature and assessed mostly in cystectomy patients. Based on this systematic review, all patients with MIBC should be treated with RC. Neoadjuvant chemotherapy may be beneficial for patients with micropapillary, plasmacytoid, sarcomatoid, and mixed variants, and especially for patients with neuroendocrine tumours. Metastatic bladder cancer should be treated as PUC. PATIENT SUMMARY: In this report, we looked at the prognosis and treatment of different bladder cancer histologies. We found that outcomes varied with divergent histologies and appropriate treatment should be based on the histological finding.
引用
- Veskimäe E, Espinos EL, Bruins HM, et al. What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review. Eur Urol Oncol. 2019. PMID: 31601522. doi:10.1016/j.euo.2019.09.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。